62 completed, 48 recruiting, 28 active not recruiting, 19 not yet recruiting. 190 Phase 2, 28 Phase 1, 8 Phase 3.
Follow pertuzumab: new trials by email Literature Review of pertuzumab trials Research Report on pertuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer Retifanlimab, Trastuzumab (Herceptin), Pertuzumab - HER2-addicted Breast Cancer | Phase 2 | Not yet recruiting | Polly A. Niravath, MD | 30 | 2026-12-31 | 2026-08-19 |
| Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 51 | 2026-12-15 | 2026-09-18 |
| HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers HLX22, Serplulimab, trastuzumab - Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis) | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 128 | 2026-12-01 | 2026-11-16 |
| SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC) | Phase 2 | Not yet recruiting | Fudan University | 358 | 2026-10-01 | 2026-10-02 |
| Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer Fulvestaciclib, Trastuzumab, Pertuzumab - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 240 | 2026-10-01 | 2026-07-21 |
| Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 31 | 2026-09-01 | 2026-10-19 |
| Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer Culmerciclib, Letrozole, Trastuzumab (TQB211) - Breast Cancer, HR Positive, HER2 Positive Breast Cancer | Phase 2 | Not yet recruiting | Shengjing Hospital | 33 | 2026-09-01 | 2026-08-31 |
| Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Paclitaxel oral solution plus Trastuzumab and Pertuzumab - HER2 + Breast Cancer | Phase 1 / Phase 2 | Recruiting | Liu Shu | 30 | 2026-07-29 | 2026-08-04 |
| Study of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer Paclitaxel polymer micelles combined with trastuzumab, pertuzumab, and adrelumab, Taxanes combined with trastuzumab and pertuzumab. - Advanced HER2-positive Breast Cancer | Phase 2 | Recruiting | Fudan University | 140 | 2026-07-28 | 2026-11-02 |
| Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer Dalpiciclib, Trastuzumab (Herceptin), Pertuzumab - Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 57 | 2026-06-01 | 2026-05-28 |
| A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer JSKN003, Trastuzumab, Pertuzumab - HER2-positive Recurrent or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Shanghai JMT-Bio Inc. | 60 | 2026-05-30 | 2026-04-22 |
| Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer Fovinaciclib, Aromatase Inhibitors, Trastuzumab + Pertuzumab - HR+/HER2+ Early Breast Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2026-05-20 | 2026-06-01 |
| Elacestrant in Advanced Triple Positive Breast Cancer Elacestrant, Trastuzumab, Pertuzumab - ER Positive, HER2 Positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | NYU Langone Health | 50 | 2026-05-13 | 2026-05-28 |
| Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab - Breast Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 156 | 2026-05-01 | 2026-04-17 |
| Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. SHR-A1811, Pertuzumab, trastuzumab - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 100 | 2026-05-01 | 2026-04-14 |
| Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) Lipo-Dox®, Cyclophosphamide, Trastuzumab (Herceptin) - HER-2 Positive Breast Cancer | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 54 | 2026-04-30 | 2026-05-04 |
| Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer Trastuzumab, Pertuzumab, Docetaxel - HER2-positive Early-stage Breast Cancer | Phase 2 | Recruiting | Rutgers, The State University of New Jersey | 50 | 2026-03-26 | 2026-04-23 |
| Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer THP Regimen (Taxane + Trastuzumab + Pertuzumab), Trastuzumab Rezetecan (SHR-A1811) - HER2-positive Breast Cancer | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 124 | 2026-03-24 | 2026-06-15 |
| HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd) - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-03-04 | 2026-08-20 |
| A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab - HER2 + Breast Cancer | Phase 2 / Phase 3 | Recruiting | Shanghai Henlius Biotech | 706 | 2026-02-27 | 2026-03-20 |
Showing 20 of 190. Sign in to see all of them.
Breast Neoplasms (115) · Neoplasms (9) · Neoplasm Metastasis (6) · Stomach Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Colorectal Neoplasms (5) · Ovarian Neoplasms (5) · Prostatic Neoplasms (5) · Biliary Tract Neoplasms (4) · Brain Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Colonic Neoplasms (3) · Hematologic Neoplasms (3) · Inflammatory Breast Neoplasms (3) · Lung Neoplasms (3)
Hoffmann-La Roche (17) · Genentech, Inc. (12) · Dana-Farber Cancer Institute (5) · Fudan University (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · Memorial Sloan Kettering Cancer Center (4) · National Cancer Institute (NCI) (4) · Shanghai Jiao Tong University School of Medicine (4) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Shengjing Hospital (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Cancer Research UK (2) · City of Hope Medical Center (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · German Cancer Research Center (2)
United States (86) · China (39) · Italy (27) · Spain (26) · France (24) · Germany (24) · United Kingdom (20) · South Korea (12) · Belgium (11) · Brazil (11) · Canada (11) · Netherlands (11) · Australia (10) · Portugal (9) · Poland (8)
Adrienne Waks, MD (2) · Chau Dang, MD (2) · Jordan Waypa, FNP (2) · Matthew Krebs, Dr (2) · Nancy Lin, MD (2) · Aarti Bhardwaj, MD (1) · Ajay Dhakal, MBBS (1) · Alexios Matikas, MD/PhD (1) · Amy Tiersten, MD (1) · Andrea Botticelli (1) · Andrea Pirzkall, M.D. (1) · Andreas Schneeweiss, Prof. Dr. (1) · Anna Dorothea Wagner, MD (1)
PMID 28057664, PMID 20124182, PMID 21796368, PMID 22153890, PMID 22198468, PMID 22623692, PMID 22649152, PMID 23704196, PMID 24457379, PMID 24733796, PMID 25005255, PMID 26586415, PMID 26979312, PMID 27052654, PMID 27108243, PMID 27179402, PMID 27406346, PMID 27406347, PMID 27486629, PMID 27955684, PMID 28183321, PMID 28314836, PMID 28851423, PMID 29223479, PMID 29253081, PMID 29320312, PMID 29326029, PMID 29433963, PMID 30106636, PMID 30721110, PMID 30778520, PMID 30852761, PMID 30857956, PMID 31126258, PMID 31477168, PMID 31774522, PMID 31809243, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32463741, PMID 32701140, PMID 32988996, PMID 33048619, PMID 33068284, PMID 33090333, PMID 33242536, PMID 33736679, PMID 33844595, PMID 33945296
2018 (4), 2023 (4), 2014 (3), U10CA180820 (3), 2009 (2), 2017 (2), 2019 (2), 2025 (2), 2005 (1), 2016 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA043703 (1), R01CA166020 (1)